A biopharma platform company that continuously generates and deploys development-grade clinical evidence at scale.
Conventional clinical development and treatment remain linear, siloed, and fragmented — leaving patient-level response, safety, and value uncertain for patients, payers, and drug developers.
KLARITOS is building a proprietary clinical development and treatment platform for high-cost biotech therapies. The platform uses mechanism-driven precision medicine protocols to generate patient-level evidence, N=1 assurance, and evidence-rich disease cohorts during treatment.
Selected patients from those cohorts may be enrolled into regulatory-grade clinical trials that generate data supporting new or revised labels and reimbursement evidence.
Initial applications include rare disease master protocols and Alzheimer’s combination therapy programs in combination therapy programs in stratified subsets.
